Eli Lilly "peer perform"

09/15/05 - Bear Stearns

NEW YORK, September 15 (newratings.com) - Analyst John Boris of Bear Stearns maintains his "peer perform" rating on Eli Lilly & Co (LLY).

In a research note published yesterday, the analyst mentions that the market appears to be underestimating the sales potential of the company's Cymbalta and Forteo drugs. The analyst expects Eli Lilly to report the results for its Cymbalta drug for the treatment of additional indications in GAD and fibromyalgia during 2006. Bear Stearns expects the company to report the Phase II results for its Factor Xa inhibitor during the upcoming American Society of Hematology (ASH) meeting.